Thioesters

Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

Retrieved on: 
Wednesday, March 3, 2021
Clinical medicine, Fluticasone propionate, Glucocorticoids, Organofluorides, Respiratory therapy, Thioesters, Pulmonology, Health care

Following pandemic-related disruption in second quarter, we achieved consecutive all-time highs for new prescriptions of XHANCE in third and fourth quarter 2020.

Key Points: 
  • Following pandemic-related disruption in second quarter, we achieved consecutive all-time highs for new prescriptions of XHANCE in third and fourth quarter 2020.
  • The number of XHANCE (fluticasone propionate) prescriptions increased by 36% from 54,300 in the fourth quarter 2019 to 73,900 in the fourth quarter 2020.
  • The number of new prescriptions for XHANCE increased by 16% from 21,200 in the fourth quarter of 2019 to 24,600 in the fourth quarter of 2020.
  • This includes the Company's expectation that first quarter 2021 XHANCE net revenue will decrease compared to fourth quarter 2020.

DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19

Retrieved on: 
Monday, January 11, 2021
Anilides, Dalcetrapib, Thioesters, Clinical research, Coronavirus disease, Medical research, Placebo-controlled study, Health, CETP inhibitor

dal-COVID is a double-blind, placebo-controlled trial in patients with confirmed mild to moderate symptomatic COVID-19.

Key Points: 
  • dal-COVID is a double-blind, placebo-controlled trial in patients with confirmed mild to moderate symptomatic COVID-19.
  • I am delighted that dalcetrapib is being investigated as an oral antiviral treatment for mild to moderate COVID-19, said Dr.
  • Dalcetrapib is also currently being evaluated in the dal-GenE Phase 3 cardiovascular precision medicine clinical outcomes trial.
  • DalCor obtained global rights to develop, manufacture and commercialize dalcetrapib under a license and collaboration agreement with Roche.

DalCor announces dal-GenE trial continues with final data expected in the first half of 2021

Retrieved on: 
Monday, July 27, 2020
Anilides, Dalcetrapib, Thioesters, Chemistry, CETP inhibitor

This is an important milestone for DalCor and for cardiovascular patients with the ADCY9 AA genotype.

Key Points: 
  • This is an important milestone for DalCor and for cardiovascular patients with the ADCY9 AA genotype.
  • We expect the final results of the dal-GenE trial during the first half of 2021.
  • dal-GenE passed a futility analysis in January 2020 and trial completion is expected in the first half of 2021.
  • DalCor obtained global rights to develop, manufacture and commercialize dalcetrapib under a license and collaboration agreement with Roche.

Diane E. Sullivan joins DalCor Pharmaceuticals as Chief Commercial Officer

Retrieved on: 
Monday, June 8, 2020
Anilides, Dalcetrapib, Hoffmann-La Roche, Thioesters, Pharmaceutical industry, Chemistry

LONDON and MONTREAL, June 08, 2020 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the appointment of Diane E. Sullivan as Chief Commercial Officer effective June 1, 2020.

Key Points: 
  • LONDON and MONTREAL, June 08, 2020 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the appointment of Diane E. Sullivan as Chief Commercial Officer effective June 1, 2020.
  • Ms. Sullivan joins DalCor from The Medicines Company where she held the position of Chief Commercial Officer and has extensive leadership experience in both life sciences and technology at U.S. and U.K. based multi-national corporations.
  • DalCor is deeply committed to bringing forward the first precision medicine for patients with cardiovascular disease, said Ms. Sullivan.
  • DalCor holds the worldwide exclusive license for dalcetrapib, together with rights to the genetic marker for use with dalcetrapib.

DalCor announces dal-GenE trial to continue as planned following interim futility analysis

Retrieved on: 
Monday, January 27, 2020
Anilides, Dalcetrapib, Hoffmann-La Roche, Thioesters, Clinical research, DSMB, Health, Data monitoring committee, CETP inhibitor

LONDON and MONTREAL, Jan. 27, 2020 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced that following the results of the interim futility analysis of the dalcetrapib dal-GenE Phase 3 trial, DalCor will continue the dal-GenE trial as recommended by the independent Data and Safety Monitoring Board (DSMB).

Key Points: 
  • LONDON and MONTREAL, Jan. 27, 2020 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced that following the results of the interim futility analysis of the dalcetrapib dal-GenE Phase 3 trial, DalCor will continue the dal-GenE trial as recommended by the independent Data and Safety Monitoring Board (DSMB).
  • dal-GenE is the first cardiovascular precision medicine outcomes trial designed to evaluate the efficacy of dalcetrapib in 6,149 ACS patients carrying the ADCY9 AA genotype.
  • DalCor would like to thank all the patients, investigators, and study sites for their continued participation in the dal-GenE study.
  • DalCor holds the worldwide exclusive license for dalcetrapib, together with rights to the genetic marker for use with dalcetrapib.

Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial

Retrieved on: 
Tuesday, December 17, 2019
Health, RTT, Glucocorticoids, Organofluorides, Medicine, Fluticasone propionate, Respiratory therapy, Thioesters, Exhalation delivery system, Propionate, Food and Drug Administration

We are pleased to announce the publication of EXHANCE-3, the fourth major registration trial from the development program supporting the initial FDA approval of XHANCE, said Ramy Mahmoud, M.D., M.P.H., President and Chief Operating Officer of Optinose.

Key Points: 
  • We are pleased to announce the publication of EXHANCE-3, the fourth major registration trial from the development program supporting the initial FDA approval of XHANCE, said Ramy Mahmoud, M.D., M.P.H., President and Chief Operating Officer of Optinose.
  • The Optinose team would like to thank the investigators and patients who made this trial possible.
  • Data from this trial contributes importantly to understanding the clinical performance of XHANCE and would not be available today without their willingness to participate.
  • XHANCE combines a proprietary Optinose Exhalation Delivery System (EDS) for liquids with an aqueous suspension of microfine fluticasone propionate for topical intranasal administration
    Hypersensitivity to any ingredient in XHANCE.

Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

Retrieved on: 
Tuesday, November 12, 2019
RTT, Glucocorticoids, Clinical medicine, Fluticasone propionate, Organofluorides, Respiratory therapy, Thioesters, Medicine, Propionate, Pulmonology

Conference call and webcast to be held today at 4:30 p.m. Eastern Time

Key Points: 
  • Conference call and webcast to be held today at 4:30 p.m. Eastern Time
    YARDLEY, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September30, 2019, and provided recent operational highlights.
  • The number of XHANCE (fluticasone propionate) prescriptions increased by 27% from second quarter to third quarter 2019 and by 18% from September to October 2019.
  • The Company generated $8.7 million and $19.3 million of XHANCE net revenue during the three-month and nine-month periods ended September30, 2019.
  • Selling, general and administrative expenses were $25.3 million and $77.6 million during the three-month and nine-month periods ended September30, 2019.

Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile

Retrieved on: 
Thursday, April 26, 2018
Anilides, Dalcetrapib, Hoffmann-La Roche, Thioesters, CETP inhibitor

This discovery has led DalCor Pharmaceuticals to launch the Dal-GenE study with 6000 patients that is presently taking place in 34 countries.

Key Points: 
  • This discovery has led DalCor Pharmaceuticals to launch the Dal-GenE study with 6000 patients that is presently taking place in 34 countries.
  • This new discovery described today supports the underlying rationale for Dal-GenE and may explain the reasons for the cardiovascular benefits occurring in patients who have the appropriate genetic profile.
  • The company's development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients.
  • DalCor Pharmaceuticals has offices in Montreal, San Mateo, Calif., Zug, Switzerland and Stockport, U.K. For more information, visit www.dalcorpharma.com